Furanodienone inhibits cell proliferation and survival by suppressing ERα signaling in human breast cancer MCF-7 cells

Journal of Cellular Biochemistry

Volumn 112, Issue 1, 2011, Pages 217-224

  Li, Ying Wei ^a   Zhu, Guo Yuan ^a   Shen, Xiao Ling ^a   Chu, Jian Hong ^a   Yu, Zhi Ling ^a   Fong, Wang Fun ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Breast cancer; Estrogen receptor alpha; Furanodienone; MCF 7

Indexed keywords

ANTINEOPLASTIC AGENT; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FURANODIENONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL EVALUATION; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; ESTROGEN RESPONSIVE ELEMENT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; FURANS; HUMANS; SESQUITERPENES; SIGNAL TRANSDUCTION;

EID: 78651333281     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22922     Document Type: Article

References (29)

1. Arpino G, Wiechmann L, Osborne CK, Schiff R. 2008. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29:217-233.
2. Balan KV, Wang Y, Chen SW, Chen JC, Zheng LF, Yang L, Liu ZL, Pantazis P, Wyche JH, Han Z. 2006. Proteasome-independent down-regulation of estrogen receptor-alpha (ERalpha) in breast cancer cells treated with 4,40-dihydroxy- trans-stilbene. Biochem Pharmacol 72:573-581.
3. Bjornstrom L, Sjoberg M. 2005. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:833-842.
4. Blander CL. 2006. Estrogens and breast cancer. N Engl J Med 354:1647-1648; author reply 1647-1648.
5. Buzdar AU, Robertson JF. 2006. Fulvestrant: Pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother 40:1572-1583.
6. Ding J, Feng Y, Wang HY. 2007. From cell signaling to cancer therapy. Acta Pharmacol Sin 28:1494-1498.
7. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K. 2007. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: A result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 13:4882-4890.
8. Houghton P, Fang R, Techatanawat I, Steventon G, Hylands PJ, Lee CC. 2007. The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. Methods 42:377-387.
9. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
10. Jordan VC, Brodie AM. 2007. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72:7-25.
11. Klinge CM. 2001. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29:2905-2919.
12. Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y, Ip C, Onate SA, Gao AC. 2005. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res 65:3487-3492. (Pubitemid 40524636)
13. Li X, Wang G, Zhao J, Ding H, Cunningham C, Chen F, Flynn DC, Reed E, Li QQ. 2005. Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci 62:894-904.
14. Ma E, Wang X, Li Y, Sun X, Tai W, Li T, Guo T. 2008. Induction of apoptosis by furanodiene in HL60 leukemia cells through activation of TNFR1 signaling pathway. Cancer Lett 271:158-166.
15. Makabe H, Maru N, Kuwabara A, Kamo T, Hirota M. 2006. Anti-inflammatory sesquiterpenes from Curcuma zedoaria. Nat Prod Res 20:680-685.
16. Massarweh S, Schiff R. 2006. Resistance to endocrine therapy in breast cancer: Exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13(Suppl 1): S15-S24.
17. Morandi P. 2005. Advances in the treatment of breast cancer. Womens Health (Lond Engl) 1:359-363.
18. Musgrove EA, Sergio CM, Anderson LR, Inman CK, McNeil CM, Alles MC, Gardiner-Garden M, Ormandy CJ, Butt AJ, Sutherland RL. 2008. Identification of downstream targets of estrogen and c-myc in breast cancer cells. Adv Exp Med Biol 617:445-451.
19. Platet N, Cathiard AM, Gleizes M, Garcia M. 2004. Estrogens and their receptors in breast cancer progression: A dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51:55-67.
20. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. 1998. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 18:4499-4508.
21. Ricote M, Garcia-Tunon I, Fraile B, Fernandez C, Aller P, Paniagua R, Royuela M. 2006. P38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells. Apoptosis 11:1969-1975.
22. Srinivasan S, Koduru S, Kumar R, Venguswamy G, Kyprianou N, Damodaran C. 2009. Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. Int J Cancer 125:961-967.
23. Sundar SN, Kerekatte V, Equinozio CN, Doan VB, Bjeldanes LF, Firestone GL. 2006. Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells. Mol Endocrinol 20:3070-3082.
24. Tanaka K, Kuba Y, Ina A, Watanabe H, Komatsu K. 2008. Prediction of cyclooxygenase inhibitory activity of Curcuma rhizome from chromatograms by multivariate analysis. Chem Pharm Bull (Tokyo) 56:936-940.
25. Tse AK, Wan CK, Shen XL, Zhu GY, Cheung HY, Yang M, Fong WF. 2007a. 1,25-Dihydroxyvitamin D3 induces biphasic NF-kappaB responses during HL-60 leukemia cells differentiation through protein induction and PI3K/ Akt-dependent phosphorylation/degradation of IkappaB. Exp Cell Res 313:1722-1734.
26. Tse AK, Wan CK, Zhu GY, Shen XL, Cheung HY, Yang M, Fong WF. 2007b. Magnolol suppresses NF-kappaB activation and NF-kappaB regulated gene expression through inhibition of IkappaB kinase activation. Mol Immunol 44:2647-2658.
27. Wang G, Li X, Huang F, Zhao J, Ding H, Cunningham C, Coad JE, Flynn DC, Reed E, Li QQ. 2005. Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci 62:881-893.
28. Wang W, Yang S, Su Y, Xiao Z, Wang C, Li X, Lin L, Fenton BM, Paoni SF, Ding I, Keng P, Okunieff P, Zhang L. 2007. Enhanced antitumor effect of combined triptolide and ionizing radiation. Clin Cancer Res 13:4891-4899.
29. Xiao Y, Yang FQ, Li SP, Gao JL, Hu G, Lao SC, Conceicao EL, Fung KP, Wangl YT, Lee SM. 2007. Furanodiene induces G2/M cell cycle arrest and apoptosis through MAPK signaling and mitochondria-caspase pathway in human hepatocellular carcinoma cells. Cancer Biol Ther 6:1044-1050.